Douglas Leipold

Douglas Leipold

Auto-generated profile, based on publicly available information

Douglas Leipold

Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
TPThomas Pillow
Thomas Pillow
PAPragya Adhikari
Pragya Adhikari
RBRobert A. Blake
Robert A. Blake
JCJinhua Chen
Jinhua Chen
GRGeoffrey Del Rosario
Geoffrey Del Rosario
PDPeter S. Dragovich
Peter S. Dragovich

28 January 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
NZNeelie Zacharias
Neelie Zacharias
VPVladimir N. Podust
Vladimir N. Podust
KKKimberly K. Kajihara
Kimberly K. Kajihara
DLDouglas Leipold
Douglas Leipold
GRGeoffrey Del Rosario
Geoffrey Del Rosario
JSJack Sadowsky
Jack Sadowsky
Efficiency of targeted cell delivery of small molecules was enhanced in cells and animals via a novel well-defined bioconjugation platform combining site-specific antibody conjugation and XTEN polypeptides to enable high payload loading.

11 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GLGail D. Lewis
Gail D. Lewis
GLGuangmin Li
Guangmin Li
JGJun Guo
Jun Guo
SYShang-Fan Yu
Shang-Fan Yu
CFCarter T. Fields
Carter T. Fields
ECEunpi Cho
Eunpi Cho
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzumab for binding, conjugated to a reduced potency PBD (pyrrolobenzodiazepine) dimer payload. PBDs are potent cytotoxic agents that alkylate and cross-link DNA. In our study, the PBD dimer is modified to alkylate, but not cross-link DNA. This HER2 ADC, DHES0815A, demonstrates in vivo efficacy in models of HER2-positive and HER2-low cancers and is well-tolerated in cynomolgus monkey safety studies. Mechanisms of action include induction of DNA damage and apoptosis, activity in non-dividing cells, and bystander activity. A dose-escalation study (ClinicalTrials.gov: NCT03451162) in patients with HER2-positive metastatic breast cancer, with the primary objective of evaluating the safety and tolerability of DHES0815A and secondary objectives of characterizing the pharmacokinetics, objective response rate, duration of response, and formation of anti-DHES0815A antibodies, is reported herein. Despite early signs of anti-tumor activity, patients at higher doses develop persistent, non-resolvable dermal, ocular, and pulmonary toxicities, which led to early termination of the phase 1 trial.

10 November 2018 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
DLDouglas Leipold
Douglas Leipold
SPSaileta Prabhu
Saileta Prabhu
The design and development of therapeutic monoclonal antibodies (mAbs) through optimizing their pharmacokinetic (PK) and pharmacodynamic (PD) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challenges in therapeutic antibody design, where improving one antibody property can sometimes lead to changes in others. Here, we discuss optimization approaches for PK/PD properties of therapeutic mAbs.

15 March 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
BVBreanna S. Vollmar
Breanna S. Vollmar
CFChris Frantz
Chris Frantz
MSMelissa M. Schutten
Melissa M. Schutten
FZFiona Zhong
Fiona Zhong
GRGeoffrey del Rosario
Geoffrey del Rosario
TPThomas Pillow
Thomas Pillow
Calicheamicin antibody–drug conjugates (ADCs) are effective therapeutics for leukemias with two recently approved in the United States: Mylotarg (gemtuzumab ozogamicin) targeting CD33 for acute myeloid leukemia and Besponsa (inotuzumab ozogamicin) targeting CD22 for acute lymphocytic leukemia. Both of these calicheamicin ADCs are heterogeneous, aggregation-prone, and have a shortened half-life due to the instability of the acid-sensitive hydrazone linker in circulation. We hypothesized that we could improve upon the heterogeneity, aggregation, and circulation stability of calicheamicin ADCs by directly attaching the thiol of a reduced calicheamicin to an engineered cysteine on the antibody via a disulfide bond to generate a linkerless and traceless conjugate. We report herein that the resulting homogeneous conjugates possess minimal aggregation and display high in vivo stability with 50% of the drug remaining conjugated to the antibody after 21 days. Furthermore, these calicheamicin ADCs are highly efficacious in mouse models of both solid tumor (HER2+ breast cancer) and hematologic malignancies (CD22+ non-Hodgkin lymphoma). Safety studies in rats with this novel calicheamicin ADC revealed an increased tolerability compared with that reported for Mylotarg. Overall, we demonstrate that applying novel linker chemistry with site-specific conjugation affords an improved, next-generation calicheamicin ADC.

22 May 2019 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
CLChunze Li
Chunze Li
CZCindy Zhang
Cindy Zhang
RDRong Deng
Rong Deng
DLDouglas Leipold
Douglas Leipold
DLDongwei Li
Dongwei Li
AKAmrita V. Kamath
Amrita V. Kamath
Prediction of human pharmacokinetics (PK) based on preclinical information for antibody–drug conjugates (ADCs) provide important insight into first‐in‐human (FIH) study design. This retrospective analysis was conducted to identify an appropriate scaling method to predict human PK for ADCs from animal PK data in the linear range. Different methods for projecting human clearance (CL) from animal PK data for 11 ADCs exhibiting linear PK over the tested dose ranges were examined: multiple species allometric scaling (CL vs. body weight), allometric scaling with correction factors, allometric scaling based on rule of exponent, and scaling from only cynomolgus monkey PK data. Two analytes of interest for ADCs, namely total antibody and conjugate (measured as conjugated drug or conjugated antibody), were assessed. Percentage prediction errors (PEs) and residual sum of squares (RSS) were compared across methods. Human CL was best estimated using cynomolgus monkey PK data alone and an allometric scaling exponent of 1.0 for CL. This was consistently observed for both conjugate and total antibody analytes. Other scaling methods either underestimated or overestimated human CL, or produced larger average absolute PEs and RSS. Human concentration‐time profiles were also reasonably predicted from the cynomolgus monkey data using species‐invariant time method with a fixed exponent of 1.0 for CL and 1.0 for volume of distribution. In conclusion, results from this retrospective analysis of 11 ADCs indicate that allometric scaling of CL with an exponent of 1.0 using cynomolgus monkey PK data alone can successfully project human PK profiles of an ADC within linear range.